Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) and Revolution Medicines (NASDAQ:RVMD – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.
Valuation and Earnings
This table compares Viridian Therapeutics and Revolution Medicines”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Viridian Therapeutics | $70.85 million | 29.13 | -$342.60 million | ($3.37) | -5.41 |
| Revolution Medicines | $11.58 million | 3,487.93 | -$1.13 billion | ($8.82) | -21.37 |
Analyst Ratings
This is a summary of current ratings for Viridian Therapeutics and Revolution Medicines, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Viridian Therapeutics | 1 | 0 | 12 | 0 | 2.85 |
| Revolution Medicines | 1 | 1 | 21 | 1 | 2.92 |
Viridian Therapeutics presently has a consensus price target of $38.69, indicating a potential upside of 112.36%. Revolution Medicines has a consensus price target of $234.76, indicating a potential upside of 24.58%. Given Viridian Therapeutics’ higher possible upside, equities research analysts plainly believe Viridian Therapeutics is more favorable than Revolution Medicines.
Profitability
This table compares Viridian Therapeutics and Revolution Medicines’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Viridian Therapeutics | -505.86% | -72.97% | -42.80% |
| Revolution Medicines | N/A | -88.20% | -57.85% |
Insider and Institutional Ownership
94.3% of Revolution Medicines shares are owned by institutional investors. 2.4% of Viridian Therapeutics shares are owned by insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Volatility & Risk
Viridian Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.
Summary
Revolution Medicines beats Viridian Therapeutics on 8 of the 15 factors compared between the two stocks.
About Viridian Therapeutics
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
About Revolution Medicines
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company’s RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
